查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1841958

美国血液检测市场规模、份额和趋势分析报告：按检测类型和细分市场预测，2025-2033 年

U.S. Blood Testing Market Size, Share & Trends Analysis Report By Test Type, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国血液检测市场摘要

预计 2024 年美国血液检测市场规模将达到 359 亿美元，到 2033 年将达到 714.1 亿美元，2025 年至 2033 年的复合年增长率为 8.1%。

糖尿病、心血管疾病和癌症等慢性疾病的发生率不断上升是该市场的主要驱动力，这些疾病需要频繁的诊断测试和监测才能有效管理。

预防性医疗保健的转变以及社会意识的增强，鼓励人们定期体检和筛检，以便及早发现疾病，是推动这一市场发展的主要动力。 2024年，美国疾病管制与预防中心 (CDC) 加强了其核心检测能力，以检测和应对高优先病原体。近期的技术创新提高了血液检测的可及性和效率，成为市场扩张的重要催化剂。例如，2024年6月，美国食品药物管理局 (FDA) 批准了第一个照护现场C型肝炎病毒(HCV) RNA 检测的上市许可。此检测只需透过指尖采血样本，即可在一次就诊中完成检测和治疗。

预计将影响该市场的其他关键技术进步包括：

人工智慧的整合：人工智慧和机器学习在解读复杂的血液检测数据、实现更早的疾病检测、自动化抹片分析、改进生物标记识别以及减少诊断错误方面发挥着至关重要的作用。这些系统加快了结果交付速度，并在灵敏度和特异性方面达到甚至超过了临床金标准。

实验室晶片技术：微型设备能够在一次滴血中处理多项血液测试，从而大大减少实验室需求，改善偏远和资源有限地区的使用，并支援快速的照护现场诊断。

穿戴式生物感测器和智慧型装置（如葡萄糖和血红蛋白追踪器）现在可以实现即时、连续的血液成分监测，当与远端医疗平台相结合时，可以改善慢性病管理、患者参与度以及对健康状况变化的快速反应。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国血液检测市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国血液检测市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国血液检测市场：检测类型估计与趋势分析

  • 测试类型细分仪表板
  • 美国血液检测市场：检测类型变化分析
  • 美国血液检测市场规模与趋势分析（按检测类型，2021-2033）
  • 血糖检测
  • A1C 测试
  • 直接 LDL 检测
  • 血脂检查
  • 摄护腺特异性抗原检测
  • COVID-19检测
  • 尿素氮检测
  • 维生素D检测
  • 甲状腺刺激素检测
  • 血清尼古丁/可替宁检测
  • 高敏感CRP检测
  • 睪酮测试
  • ALT 测试
  • 皮质醇测试
  • 肌酸酐检测
  • AST测试
  • 其他血液检查

第五章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • Key company heat map analysis, 2024
  • 公司简介
    • Abbott
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories, Inc.
    • BIOMERIEUX
    • Biomerica
    • BD
    • Quest Diagnostics Incorporated
    • Siemens Healthineers AG
    • Danaher Corporation
    • Trinity Biotech Plc
Product Code: GVR-4-68040-754-0

U.S. Blood Testing Market Summary

The U.S. blood testing market size was valued at USD 35.90 billion in 2024 and is projected to reach USD 71.41 billion by 2033, growing at a CAGR of 8.1% from 2025 to 2033. The market is primarily driven by the rising prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer, which necessitate frequent diagnostic testing and monitoring for effective management.

Growing public awareness and a shift toward preventive healthcare, encouraging routine check-ups and early disease detection screening, are the major drivers for this market. In 2024, the Centers for Disease Control and Prevention (CDC) strengthened its core laboratory capabilities to detect and respond to high-priority pathogens. Recent technological innovations are a major catalyst for the market's expansion, improving the accessibility and efficiency of blood testing. For instance, in June 2024, the FDA granted marketing authorization for the first point-of-care Hepatitis C virus (HCV) RNA test, which enables single-visit testing and treatment using a fingertip blood sample.

Other key technological advances that are expected to impact this market are:

Artificial Intelligence Integration: AI and machine learning were pivotal in interpreting complex blood test data, enabling earlier disease detection, automation of smear analysis, improved biomarker identification, and reduced diagnostic errors. These systems accelerated result delivery and matched or exceeded clinical gold standards in sensitivity and specificity.

Lab-on-a-Chip Technology: Miniaturized devices capable of processing multiple blood tests on a single drop dramatically reduce laboratory demands, increasing access in remote and resource-limited regions while supporting rapid point-of-care diagnostics.

Wearable Biosensors: Smart devices (e.g., glucose and hemoglobin trackers) became possible for monitoring real-time, continuous blood composition. These are integrated with telemedicine platforms, improving chronic disease management, patient engagement, and rapid response to changes in health.

U.S. Blood Testing Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. blood testing market report based on test type:

  • Test Type Outlook (Revenue, USD Billion, 2021 - 2033)
    • Glucose Testing
    • A1C Testing
    • Direct LDL testing
    • Lipid panel testing
    • Prostate-specific antigen testing
    • COVID-19 testing
    • BUN testing
    • Vitamin D testing
    • Thyroid-stimulating hormone testing
    • Serum Nicotine / Cotinine testing
    • High sensitivity CRP testing
    • Testosterone testing
    • ALT testing
    • Cortisol testing
    • Creatinine testing
    • AST testing
    • Other blood tests

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Blood Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Blood Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Blood Testing Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Segment Dashboard
  • 4.2. U.S. Blood Testing Market: Test Type Movement Analysis
  • 4.3. U.S. Blood Testing Market Size & Trend Analysis, by Test Type, 2021 to 2033 (USD Billion)
  • 4.4. Glucose Testing
    • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.5. A1C Testing
    • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.6. Direct LDL testing
    • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.7. Lipid Panel Testing
    • 4.7.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.8. Prostate-Specific Antigen Testing
    • 4.8.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.9. Covid-19 Testing
    • 4.9.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.10. BUN Testing
    • 4.10.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.11. Vitamin D Testing
    • 4.11.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.12. Thyroid-Stimulating Hormone Testing
    • 4.12.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.13. Serum Nicotine/Cotinine Testing
    • 4.13.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.14. High Sensitivity CRP Testing
    • 4.14.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.15. Testosterone Testing
    • 4.15.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.16. ALT Testing
    • 4.16.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.17. Cortisol Testing
    • 4.17.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.18. Creatinine Testing
    • 4.18.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.19. AST Testing
    • 4.19.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.20. Other Blood Tests
    • 4.20.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 5.2. Company/Competition Categorization
  • 5.3. Vendor Landscape
    • 5.3.1. Key company heat map analysis, 2024
  • 5.4. Company Profiles
    • 5.4.1. Abbott
      • 5.4.1.1. Company overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. F. Hoffmann-La Roche Ltd
      • 5.4.2.1. Company overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. Bio-Rad Laboratories, Inc.
      • 5.4.3.1. Company overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. BIOMERIEUX
      • 5.4.4.1. Company overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. Biomerica
      • 5.4.5.1. Company overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. BD
      • 5.4.6.1. Company overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. Quest Diagnostics Incorporated
      • 5.4.7.1. Company overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives
    • 5.4.8. Siemens Healthineers AG
      • 5.4.8.1. Company overview
      • 5.4.8.2. Financial performance
      • 5.4.8.3. Product benchmarking
      • 5.4.8.4. Strategic initiatives
    • 5.4.9. Danaher Corporation
      • 5.4.9.1. Company overview
      • 5.4.9.2. Financial performance
      • 5.4.9.3. Product benchmarking
      • 5.4.9.4. Strategic initiatives
    • 5.4.10. Trinity Biotech Plc
      • 5.4.10.1. Company overview
      • 5.4.10.2. Financial performance
      • 5.4.10.3. Product benchmarking
      • 5.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. blood testing market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Table 3 U.S. blood testing market, by test type, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. blood testing market: market outlook
  • Fig. 10 Blood testing competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. blood testing market driver impact
  • Fig. 16 U.S. blood testing market restraint impact
  • Fig. 17 U.S. blood testing market strategic initiatives analysis
  • Fig. 18 U.S. blood testing market: Test type movement analysis
  • Fig. 19 U.S. blood testing market: Test type outlook and key takeaways
  • Fig. 20 Glucose testing market estimates and forecast, 2021 - 2033
  • Fig. 21 A1C testing market estimates and forecast, 2021 - 2033
  • Fig. 22 Direct LDL testing market estimates and forecast, 2021 - 2033
  • Fig. 23 Lipid panel testing market estimates and forecast, 2021 - 2033
  • Fig. 24 Prostate-specific antigen testing market estimates and forecast, 2021 - 2033
  • Fig. 25 COVID-19 testing market estimates and forecast, 2021 - 2033
  • Fig. 26 BUN testing market estimates and forecast, 2021 - 2033
  • Fig. 27 Vitamin D testing market estimates and forecast, 2021 - 2033
  • Fig. 28 Thyroid-stimulating hormone (TSH) market estimates and forecast, 2021 - 2033
  • Fig. 29 Serum nicotine/cotinine market estimates and forecast, 2021 - 2033
  • Fig. 30 High sensitivity CRP testing market estimates and forecast, 2021 - 2033
  • Fig. 31 Testosterone testing market estimates and forecast, 2021 - 2033
  • Fig. 32 ALT testing market estimates and forecast, 2021 - 2033
  • Fig. 33 Cortisol testing market estimates and forecast, 2021 - 2033
  • Fig. 34 Creatinine testing market estimates and forecast, 2021 - 2033
  • Fig. 35 AST testing market estimates and forecast, 2021 - 2033
  • Fig. 36 Other blood tests market estimates and forecast, 2021 - 2033